Stay updated on Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Sign up to get notified when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.

Latest updates to the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page
- Check5 days agoChange DetectedThe site revision was updated from v3.5.0 to v3.5.2. No visible changes to study details or navigation.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded the term 'Mucopolysaccharidosis, MPS-II' and removed 'Mucopolysaccharidosis type 2' from the study's glossary/keywords.SummaryDifference0.1%

- Check33 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed.SummaryDifference0.1%

- Check41 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision: v3.4.2 was added to the page. The funding-lapse/open-status notice and the previous Revision: v3.4.1 entry were removed.SummaryDifference0.5%

- Check76 days agoChange DetectedAdded a site-wide notice about government funding and operating status, and updated the page version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.